title: Electroacupuncture mediates extracellular signal-regulated kinase 1/2 pathways in the spinal cord of rats with inflammatory pain.
abstract: BACKGROUND
  Activation of extracellular signal-regulated kinase1/2 (ERK1/2) in dorsal horn of the spinal cord by peripheral inflammation is contributed to inflammatory pain hypersensitivity. Although electroacupuncture (EA) has been widely used to alleviate various kinds of pain, the underlying mechanism of EA analgesia requires further investigation. This study investigated the relationship between EA-induced analgesia and ERK signaling involved in pain hypersensitivity.
  
  
  METHODS
  The rats were randomly divided into control, model, EA and sham EA groups. Inflammatory pain model was induced by injecting of 100 μl Complete Freund's adjuvant (CFA) into the plantar surface of a hind paw. Rats in the EA group were treatment with EA (constant aquare wave, 2 Hz and 100 Hz alternating frequencies, intensities ranging from 1-2 mA) at 5.5 h, 24.5 h and 48.5 h. Paw withdrawal thresholds (PWTs) were measured before modeling and at 5 h, 6 h, 25 h and 49 h after CFA injection. Rats were killed and ipsilateral side of the lumbar spinal cords were harvested for detecting the expressions of p-ERK1/2, Elk1, COX-2, NK-1 and CREB by immunohistochemistry, real-time PCR, western blot analysis and EMSA. Finally, the analgesic effect of EA plus U0126, a MEK (ERK kinase) inhibitor, on CFA rats was examined.
  
  
  RESULTS
  Inflammatory pain was induced in rats by hindpaw injection of CFA and significantly increased phospho-ERK1/2 positive cells and protein levels of p-ERK1/2 in the ipsilateral spinal cord dorsal horn (SCDH). CFA up-regulated of cyclooxygenase-2 (COX-2) mRNA and protein expression at 6 h after injection and neurokinin-1 receptor (NK-1) expression at 49 h post-injection, in the SCDH. EA, applied to Zusanli (ST36) and Kunlun (BL60), remarkably increased the pain thresholds of CFA injected rats, significantly suppressed ERK1/2 activation and COX-2 protein expression after a single treatment, and decreased NK-1 mRNA and protein expression at 49 h. EA decreased the DNA binding activity of cAMP response element binding protein (CREB), a downstream transcription factor of ERK1/2, at 49 h after CFA injection. Moreover, EA and U0126 synergistically inhibited CFA-induced allodynia.
  
  
  CONCLUSIONS
  The present study suggests that EA produces analgesic effect by preventing the activation of ERK1/2-COX-2 pathway and ERK1/2-CREB-NK-1 pathway in CFA rats.
authors.affiliation: Department of Neurobiology & Acupuncture Research, the Third Clinical College, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang Province 310053, China. fangjianqiao7532@163.com.
authors.forename: Jian-Qiao
authors.initials: JQ
authors.lastname: Fang
authors.forename: Jun-Fan
authors.initials: JF
authors.lastname: Fang
authors.forename: Yi
authors.initials: Y
authors.lastname: Liang
authors.forename: Jun-Ying
authors.initials: JY
authors.lastname: Du
mesh_terms: D000818:Animals; D002070:Butadienes / Q000494:pharmacology; D015671:Electroacupuncture / Q000379:methods*; D006930:Hyperalgesia / Q000139:chemically induced / Q000628:therapy; D020935:MAP Kinase Signaling System; D008297:Male; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D009570:Nitriles / Q000494:pharmacology; D010146:Pain / Q000201:enzymology; D059408:Pain Management / Q000379:methods*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000201:enzymology / Q000502:physiology*
chemical_list: D002070:Butadienes; D009570:Nitriles; C113580:U 0126; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
references.citation: Exp Neurol. 2005 Oct;195(2):430-6
references.pmid: 16054138
references.citation: Brain Res Rev. 2009 Apr;60(1):135-48
references.pmid: 19150373
references.citation: Nat Neurosci. 1999 Dec;2(12):1114-9
references.pmid: 10570489
references.citation: Am J Chin Med. 2006;34(6):981-8
references.pmid: 17163587
references.citation: Neurobiol Dis. 2001 Feb;8(1):1-10
references.pmid: 11162235
references.citation: Zhongguo Zhen Jiu. 2012 Nov;32(11):1007-11
references.pmid: 23213989
references.citation: Mol Pain. 2013 Mar 22;9:13
references.pmid: 23517865
references.citation: J Neurosci. 1997 Oct 15;17(20):8049-60
references.pmid: 9315923
references.citation: J Pain. 2000 Sep;1(3 Suppl):57-65
references.pmid: 14622844
references.citation: Neuron. 2002 Sep 26;36(1):57-68
references.pmid: 12367506
references.citation: Am J Chin Med. 2004;32(2):269-79
references.pmid: 15315264
references.citation: Brain Res Bull. 2004 Mar 15;63(2):99-103
references.pmid: 15130698
references.citation: Anesthesiology. 2014 Feb;120(2):482-503
references.pmid: 24322588
references.citation: Eur J Neurosci. 2004 Jun;19(12):3375-81
references.pmid: 15217394
references.citation: Pain. 1996 Sep;67(1):151-161
references.pmid: 8895243
references.citation: Toxicon. 2008 May;51(6):994-1007
references.pmid: 18328523
references.citation: In Vivo. 1999 Jul-Aug;13(4):311-8
references.pmid: 10586371
references.citation: Neuron. 1998 Jun;20(6):1063-6
references.pmid: 9655494
references.citation: J Neurosci. 2001 Aug 15;21(16):5847-53
references.pmid: 11487607
references.citation: Mol Pain. 2007 Oct 31;3:32
references.pmid: 17974009
references.citation: Pain. 2004 Sep;111(1-2):125-35
references.pmid: 15327816
references.citation: Evid Based Complement Alternat Med. 2012;2012:568273
references.pmid: 21860653
references.citation: J Neurosci. 2002 Jan 15;22(2):478-85
references.pmid: 11784793
references.citation: Arthritis Care Res (Hoboken). 2010 Sep;62(9):1229-36
references.pmid: 20506122
references.citation: Phys Med Rehabil Clin N Am. 2014 May;25(2):457-70
references.pmid: 24787343
references.citation: BMC Complement Altern Med. 2014 Mar 07;14:92
references.pmid: 24606810
references.citation: J Clin Invest. 2009 Feb;119(2):287-94
references.pmid: 19127021
references.citation: BMC Complement Altern Med. 2013 Jun 15;13:134
references.pmid: 23768044
references.citation: EMBO J. 2002 Sep 16;21(18):4831-40
references.pmid: 12234923
references.citation: Glia. 2008 Apr 15;56(6):619-32
references.pmid: 18240315
references.citation: Pain. 2011 Mar;152(3 Suppl):S41-S48
references.pmid: 21078546
references.citation: J Neurosci. 2004 Sep 22;24(38):8310-21
references.pmid: 15385614
references.citation: J Neurosci. 1999 Sep 1;19(17):7670-8
references.pmid: 10460273
references.citation: Anesth Analg. 1999 Nov;89(5):1203-8
references.pmid: 10553835
references.citation: Neurosci Lett. 2005 Aug 26;384(3):339-43
references.pmid: 15908113
references.citation: Prog Neurobiol. 2008 Aug;85(4):355-75
references.pmid: 18582529
references.citation: Oncogene. 2007 May 3;26(20):2885-93
references.pmid: 17146445
references.citation: J Neurosci. 1994 Feb;14(2):712-20
references.pmid: 8301359
references.citation: Brain Res. 2005 Sep 28;1057(1-2):181-5
references.pmid: 16139820
references.citation: Neuron. 2002 Aug 15;35(4):605-23
references.pmid: 12194863
references.citation: J Neurosci. 2000 Jun 15;20(12):4563-72
references.pmid: 10844026
references.citation: Nature. 2001 Mar 22;410(6827):471-5
references.pmid: 11260714
references.citation: Brain Res Mol Brain Res. 1998 Jan;53(1-2):260-9
references.pmid: 9473689
references.citation: Exp Neurol. 2007 Dec;208(2):323-32
references.pmid: 17936754
references.citation: Physiol Rev. 1999 Jan;79(1):143-80
references.pmid: 9922370
references.citation: Science. 1992 Aug 28;257(5074):1276-9
references.pmid: 1381521
references.citation: J Neurosci. 2001 Jun 1;21(11):3771-9
references.pmid: 11356865
references.citation: Eur J Neurosci. 2005 Feb;21(3):773-81
references.pmid: 15733095
references.citation: Biochem Biophys Res Commun. 2005 Sep 16;335(1):132-8
references.pmid: 16055088